Cited by 2,641Clostridium difficile and Clostridium perfringens researchInfection Control in HealthcareAntimicrobial Resistance in Staphylococcus

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Burden of Clostridium difficile Infection in the United States

Open access

Lessa, Fernanda C., Mu, Yi, Bamberg, Wendy M., Beldavs, Zintars G., Dumyati, Ghinwa K., Dunn, John R., Farley, Monica M., Holzbauer, Stacy M., Meek, James I., Phipps, Erin C., Wilson, Lucy E., Winston, Lisa G., Cohen, Jessica A., Limbago, Brandi M., Fridkin, Scott K., Gerding, Dale N., McDonald, L. Clifford·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1408913PMC PMC10966662

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The magnitude and scope of Clostridium difficile infection in the United States continue to evolve. METHODS: In 2011, we performed active population- and laboratory-based surveillance across 10 geographic areas in the United States to identify cases of C. difficile infection (stool specimens positive for C. difficile on either toxin or molecular assay in residents ≥ 1 year of age). Cases were classified as community-associated or health care-associated. In a sample of cases of C. difficile infection, specimens were cultured and isolates underwent molecular typing. We used regression models to calculate estimates of national incidence and total number of infections, first recurrences, and deaths within 30 days after the diagnosis of C. difficile infection. RESULTS: A total of 15,461 cases of C. difficile infection were identified in the 10 geographic areas; 65.8% were health care-associated, but only 24.2% had onset during hospitalization. After adjustment for predictors of disease incidence, the estimated number of incident C. difficile infections in the United States was 453,000 (95% confidence interval [CI], 397,100 to 508,500). The incidence was estimated to be higher among females (rate ratio, 1.26; 95% CI, 1.25 to 1.27), whites (rate ratio, 1.72; 95% CI, 1.56 to 2.0), and persons 65 years of age or older (rate ratio, 8.65; 95% CI, 8.16 to 9.31). The estimated number of first recurrences of C. difficile infection was 83,000 (95% CI, 57,000 to 108,900), and the estimated number of deaths was 29,300 (95% CI, 16,500 to 42,100). The North American pulsed-field gel electrophoresis type 1 (NAP1) strain was more prevalent among health care-associated infections than among community-associated infections (30.7% vs. 18.8%, P<0.001). CONCLUSIONS: C. difficile was responsible for almost half a million infections and was associated with approximately 29,000 deaths in 2011. (Funded by the Centers for Disease Control and Prevention.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1408913

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Self-citation
Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pépin, J., & Wilcox, M. H. (2010) · Infection Control and Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,965
Self-citation
Sampling: Design and Analysis
Ziegel, E. R., & Lohr, S. L. (2000) · Technometrics · doi:10.2307/1271491 · Cited by 2,452
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G., Thompson, A. D., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,020
Self-citation
A Predominantly Clonal Multi-Institutional Outbreak ofClostridium difficile–Associated Diarrhea with High Morbidity and Mortality
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M., Michaud, S., Bourgault, A., Nguyen, T., Frenette, C. H., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,962
Clostridium difficile infection in Europe: a hospital-based survey
Bauer, M. P., Notermans, D. W., BENTHEM, B. H. B. V., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., & Kuijper, E. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61266-4 · Cited by 1,049
The Changing Epidemiology of Clostridium difficile Infections
Freeman, J., Bauer, M. P., Baines, S. D., Corver, J., Fawley, W. N., Goorhuis, A., Kuijper, E. J., & Wilcox, M. H. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00082-09 · Cited by 838
Treatment with Monoclonal Antibodies against Clostridium difficile Toxins
Lowy, I., Molrine, D. C., Leav, B. A., Blair, B. M., Baxter, R. P., Gerding, D. N., Nichol, G. M., Thomas, W. D., Leney, M. D., Sloan, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907635 · Cited by 743
Self-citation
Burden of Clostridium difficile on the Healthcare System
Dubberke, E. R., & Olsen, M. A. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis335 · Cited by 566
Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection
Planche, T., Davies, K., Coen, P. G., Finney, J. M., Monahan, I. M., Morris, K. A., O’Connor, L., Oakley, S. J., Pope, C. F., Wren, M. W. D., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70200-7 · Cited by 436

Show all 44 references

Research works printed but not linked: 4

2005, MMWR Morb Mortal Wkly Rep, 54, 1201
Heitjan DF, 1991, J R Stat Soc Ser C Appl Stat, 40, 13
2014, Fed Regist, 79, 10524
2011, Fed Regist, 76, 51476

Sorted by citations

Items 201–300 of 1,002

Intestinal calcium and bile salts facilitate germination of Clostridium difficile spores
Kochan, T. J., Somers, M. J., Kaiser, A. M., Shoshiev, M. S., Hagan, A. K., Hastie, J. L., Giordano, N. P., Smith, A. D., Schubert, A. M., Carlson, P. E., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006443 · Cited by 95
New class of precision antimicrobials redefines role of Clostridium difficile S-layer in virulence and viability
Kirk, J. A., Gebhart, D., Buckley, A. M., Lok, S., Scholl, D., Douce, G. R., Govoni, G. R., & Fagan, R. P. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah6813 · Cited by 102
Epidemiology of community-acquired and recurrent Clostridioides difficile infection
Fu, Y., Luo, Y., & Grinspan, A. M. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211016248 · Cited by 103
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile ( Clostridium difficile )
Minkoff, N. Z., Aslam, S., Medina, M., Tanner‐Smith, E. E., Zackular, J. P., Acra, S. A., Nicholson, M. R., & Imdad, A. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013871.pub2 · Cited by 113
Recurrent Clostridium difficile infection: From colonization to cure
Shields, K. S., Araujo-Castillo, R. V., Theethira, T. G., Alonso, C. D., & Kelly, C. P. (2015) · Anaerobe · doi:10.1016/j.anaerobe.2015.04.012 · Cited by 98
Efficacy of an Optimised Bacteriophage Cocktail to Clear Clostridium difficile in a Batch Fermentation Model
Nale, J. Y., Redgwell, T. A., Millard, A. D., & Clokie, M. R. J. (2018) · Antibiotics · doi:10.3390/antibiotics7010013 · Cited by 93
Epidemiology of Clostridium difficile in infants in Oxfordshire, UK: Risk factors for colonization and carriage, and genetic overlap with regional C. difficile infection strains
Stoesser, N. E., Eyre, D. W., Quan, T. P., Godwin, H., Pill, G., Mbuvi, E., Vaughan, A., Griffiths, D., Martin, J. S. H., Fawley, W. N., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182307 · Cited by 92
Structure of the full-length Clostridium difficile toxin B
Chen, P., Lam, K. H., Liu, Z., Mindlin, F. A., Chen, B., Gutierrez, C. B., Huang, L., Zhang, Y., Hamza, T., Feng, H., et al. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0268-0 · Cited by 92
Profiling Living Bacteria Informs Preparation of Fecal Microbiota Transplantations
Chu, N. D., Smith, M. B., Perrotta, A. R., Kassam, Z., & Alm, E. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170922 · Cited by 92
Metabolomic networks connect host-microbiome processes to human Clostridioides difficile infections
Robinson, J. I., Weir, W. H., Crowley, J. R., Hink, T., Reske, K. A., Kwon, J. H., Burnham, C. D., Dubberke, E. R., Mucha, P. J., & Henderson, J. P. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126905 · Cited by 91
The Phylogeny and Biological Function of Gastric Juice—Microbiological Consequences of Removing Gastric Acid
Martinsen, T. C., Fossmark, R., & Waldum, H. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236031 · Cited by 96
C. difficile exploits a host metabolite produced during toxin-mediated disease
Pruss, K. M., & Sonnenburg, J. L. (2021) · Nature · doi:10.1038/s41586-021-03502-6 · Cited by 89
Epidemiology and Prevention of Healthcare-Associated Infections in Geriatric Patients: A Narrative Review
Cristina, M. L., Spagnolo, A. M., Giribone, L., Demartini, A., & Sartini, M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105333 · Cited by 107
Type IV pili promote early biofilm formation byClostridium difficile
Maldarelli, G. A., Piepenbrink, K. H., Scott, A. J., Freiberg, J. A., Song, Y., Achermann, Y., Ernst, R. K., Shirtliff, M. E., Sundberg, E. J., Donnenberg, M. S., et al. (2016) · Pathogens and Disease · doi:10.1093/femspd/ftw061 · Cited by 97
Chronic Inflammatory Diseases and Green Tea Polyphenols
Oz, H. S. (2017) · Nutrients · doi:10.3390/nu9060561 · Cited by 90
Antibiotic Resistances of Clostridium difficile
Spigaglia, P., Mastrantonio, P., & Barbanti, F. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72799-8_9 · Cited by 90
Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids
Winston, J. A., Rivera, A. J., Cai, J., Thanissery, R., Montgomery, S. A., Patterson, A. D., & Theriot, C. M. (2020) · Infection and Immunity · doi:10.1128/iai.00045-20 · Cited by 91
Host immunity modulates the efficacy of microbiota transplantation for treatment of Clostridioides difficile infection
Littmann, E. R., Lee, J.-J., Denny, J. E., Alam, Z., Maslanka, J. R., Zarin, I., Matsuda, R., Carter, R. A., Susac, B., Saffern, M. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20793-x · Cited by 88
An ecological framework to understand the efficacy of fecal microbiota transplantation
Xiao, Y., Angulo, M. T., Lao, S., Weiss, S. T., & Liu, Y.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-17180-x · Cited by 89
Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers
Bézay, N., Ayad, A., Dubischar, K. L., Firbas, C., Hochreiter, R., Kiermayr, S., Kiss, I., Pinl, F., Jilma, B., & Westritschnig, K. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.03.098 · Cited by 89
Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial
Kokai‐Kun, J. F., Roberts, T., Coughlin, O., Le, C., Whalen, H., Stevenson, R. W., Wacher, V. J., & Sliman, J. A. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30731-x · Cited by 89
Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study
Langdon, A. E., Schwartz, D. J., Bulow, C., Sun, X., Hink, T., Reske, K. A., Jones, C. R., Burnham, C. D., Dubberke, E. R., & Dantas, G. A. (2021) · Genome Medicine · doi:10.1186/s13073-021-00843-9 · Cited by 90
Fate of Clostridia and other spore-forming Firmicute bacteria during feedstock anaerobic digestion and aerobic composting
Subirats, J., Sharpe, H., & Topp, E. (2022) · Journal of Environmental Management · doi:10.1016/j.jenvman.2022.114643 · Cited by 85
Comparison of Different Antibiotics and the Risk for Community-Associated Clostridioides difficile Infection: A Case–Control Study
Miller, A. C., Arakkal, A. T., Sewell, D. K., Segre, A. M., Tholany, J., Polgreen, P. M., & CDC MInD-Healthcare Group (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad413 · Cited by 89
Rapid change of fecal microbiome and disappearance of Clostridium difficile in a colonized infant after transition from breast milk to cow milk
Davis, M. Y., Zhang, H., Brannan, L., Carman, R. J., & Boone, J. H. (2016) · Microbiome · doi:10.1186/s40168-016-0198-6 · Cited by 88
A High-Fat/High-Protein, Atkins-Type Diet Exacerbates Clostridioides ( Clostridium ) difficile Infection in Mice, whereas a High-Carbohydrate Diet Protects
Mefferd, C. C., Bhute, S. S., Phan, J. R., Villarama, J. V., Do, D. M., Alarcia, S., Abel‐Santos, E., & Hedlund, B. P. (2020) · mSystems · doi:10.1128/msystems.00765-19 · Cited by 87
Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B
Mansfield, M. J., Tremblay, B. J.-M., Zeng, J., Wei, X., Hodgins, H., Worley, J. N., Bry, L., Dong, M., & Doxey, A. C. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009181 · Cited by 88
Reduction of Murine Colon Tumorigenesis Driven by EnterotoxigenicBacteroides fragilisUsing Cefoxitin Treatment
Shields, C. E. D., Meerbeke, S. W. V., Housseau, F., Wang, H., Huso, D. L., Casero, R. A., O’Hagan, H. M., & Sears, C. L. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw069 · Cited by 88
Pre-colonization with the commensal fungusCandida albicansreduces murine susceptibility toClostridium difficileinfection
Markey, L., Shaban, L., Green, E. R., Lemon, K. P., Mecsas, J. C., & Kumamoto, C. A. (2018) · Gut Microbes · doi:10.1080/19490976.2018.1465158 · Cited by 91
Clostridium difficile Infection Risk with Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System
Teng, C., Reveles, K. R., Obodozie-Ofoegbu, O. O., & Frei, C. R. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.30739 · Cited by 87
Clostridium difficile ribotype 017 – characterization, evolution and epidemiology of the dominant strain in Asia
Imwattana, K., Knight, D. R., Kullin, B., Collins, D. A., Putsathit, P., Kiratisin, P., & Riley, T. V. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1621670 · Cited by 87
Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis
Lee, H. S., Plechot, K., Gohil, S. K., & Lê, J. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00417-7 · Cited by 87
The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus
Johnson, D. A., Katz, P. O., Armstrong, D., Cohen, H., Delaney, B. C., Howden, C. W., Katelaris, P., Tutuian, R. I., & Castell, D. O. (2017) · Drugs · doi:10.1007/s40265-017-0712-6 · Cited by 89
The Role of Antibiotic Stewardship in Promoting Appropriate Antibiotic Use
Ha, D. R., Haste, N. M., & Gluckstein, D. P. (2017) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617700824 · Cited by 94
Durable Long-Term Bacterial Engraftment following Encapsulated Fecal Microbiota Transplantation To Treat Clostridium difficile Infection
Staley, C. M., Kaiser, T., Vaughn, B. P., Graiziger, C. T., Hamilton, M. J., Kabage, A. J., Khoruts, A., & Sadowsky, M. J. (2019) · mBio · doi:10.1128/mbio.01586-19 · Cited by 84
Surgical Infections in Low- and Middle-Income Countries: A Global Assessment of the Burden and Management Needs
Rickard, J., Beilman, G. J., Forrester, J. D., Sawyer, R. G., Stephen, A. H., Weiser, T. G., & Valenzuela, J. Y. (2019) · Surgical Infections · doi:10.1089/sur.2019.142 · Cited by 98
A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection
Alameh, M., Semon, A., Bayard, N. U., Pan, Y., Dwivedi, G., Knox, J. J., Glover, R. C., Rangel, P. C., Tanes, C., Bittinger, K. L., et al. (2024) · Science · doi:10.1126/science.adn4955 · Cited by 87
Outpatient Antibiotic Prescribing Practices for Uncomplicated Urinary Tract Infection in Women in the United States, 2002–2011
Kobayashi, M., Shapiro, D. J., Hersh, A. L., Sanchez, G. V., & Hicks, L. A. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw159 · Cited by 84
Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis
Beinortas, T., Burr, N. E., Wilcox, M. H., & Subramanian, V. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30285-8 · Cited by 87
Coevolutionary Governance of Antibiotic and Pesticide Resistance
Jørgensen, P. S., Folke, C., Henriksson, P. J. G., Malmros, K., Troell, M. F., & Zorzet, A. (2020) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2020.01.011 · Cited by 87
Two Distinct Patterns of Clostridium difficile Diversity Across Europe Indicating Contrasting Routes of Spread
Eyre, D. W., Davies, K., Davis, G., Fawley, W. N., Dingle, K. E., Maio, N. D., Karas, A., Crook, D. W., Peto, T., Walker, A. S., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy252 · Cited by 82
Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota
Bluemel, S., Williams, B., Knight, R. D., & Schnabl, B. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00245.2016 · Cited by 85
Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms
Banawas, S. (2018) · BioMed Research International · doi:10.1155/2018/8414257 · Cited by 83
Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease
Bushman, F. D., Conrad, M. A., Ren, Y., Zhao, C., Gu, C., Petucci, C. J., Kim, M., Abbas, A. A., Downes, K. J., Devas, N., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.07.020 · Cited by 82
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
Orenstein, R., Dubberke, E. R., Khanna, S., Lee, C., Yoho, D. S., Johnson, S., Hecht, G. A., DuPont, H. L., Gerding, D. N., Blount, K., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07256-y · Cited by 83
Self-citation
Next-Generation Probiotics Targeting Clostridium difficile through Precursor-Directed Antimicrobial Biosynthesis
Spinler, J. K., Auchtung, J. M., Brown, A., Boonma, P., Oezguen, N., Ross, C. L., Luna, R. A., Runge, J. K., Versalovic, J. A., Peniche, A. G., et al. (2017) · Infection and Immunity · doi:10.1128/iai.00303-17 · Cited by 82
Association Between Antibiotic Use and Hospital-onset Clostridioides difficile Infection in US Acute Care Hospitals, 2006–2012: An Ecologic Analysis
Kazakova, S. V., Baggs, J. M., McDonald, L. C., Yi, S. H., Hatfield, K. M., Guh, A. Y., Reddy, S. C., & Jernigan, J. A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz169 · Cited by 81
Self-citation
Food-Associated Stress Primes Foodborne Pathogens for the Gastrointestinal Phase of Infection
Horn, N. L., & Bhunia, A. K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01962 · Cited by 84
Clostridium difficile Infection: An Epidemiology Update
Roo, A. C. D., & Regenbogen, S. E. (2020) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0040-1701229 · Cited by 80
Defining and Evaluating a Core Genome Multilocus Sequence Typing Scheme for Genome-Wide Typing of Clostridium difficile
Bletz, S., Janežič, S., Harmsen, D., Rupnik, M., & Mellmann, A. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01987-17 · Cited by 80
Clostridioides (Clostridium) difficile infection in hospitalized patients with antibiotic-associated diarrhea: A systematic review and meta-analysis
Nasiri, M. J., Goudarzi, M., Hajikhani, B., Ghazi, M., Goudarzi, H., & Pouriran, R. (2018) · Anaerobe · doi:10.1016/j.anaerobe.2018.01.011 · Cited by 80
Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection
Normington, C., Moura, I. B., Bryant, J. A., Ewin, D. J., Clark, E., Kettle, M. J., Harris, H. C., Spittal, W. D., Davis, G. L., Henn, M. R., et al. (2021) · npj Biofilms and Microbiomes · doi:10.1038/s41522-021-00184-w · Cited by 84
Corrigendum: Bacteroides fragilis Prevents Clostridium difficile Infection in a Mouse Model by Restoring Gut Barrier and Microbiome Regulation
Deng, H., Yang, S., Zhang, Y., Qian, K., Zhang, Z., Liu, Y., Wang, Y., Bai, Y., Fan, H., Zhao, X., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00601 · Cited by 78
Clostridium difficile PCR Cycle Threshold Predicts Free Toxin
Senchyna, F., Gaur, R. L., Gombar, S., Truong, C., Schroeder, L. F., & Banaei, N. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00563-17 · Cited by 78
Fecal microbiota transplantation for managing irritable bowel syndrome
El‐Salhy, M., & Mazzawi, T. R. E. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1447380 · Cited by 81
Antibacterial and antivirulence activities of auranofin against Clostridium difficile
AbdelKhalek, A., Abutaleb, N. S., Mohammad, H. T., & Seleem, M. N. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.018 · Cited by 78
Clinical Practice Guideline by the Pediatric Infectious Diseases Society (PIDS) and the Infectious Diseases Society of America (IDSA): 2023 Guideline on Diagnosis and Management of Acute Bacterial Arthritis in Pediatrics
Woods, C. R., Bradley, J. S., Chatterjee, A., Kronman, M. P., Arnold, S. R., Robinson, J., Copley, L. A., Arrieta, A. C., Fowler, S. L., Harrison, C., et al. (2023) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piad089 · Cited by 84
Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life
Wilcox, M. H., Ahir, H., Coia, J. E., Dodgson, A. R., Hopkins, S., Llewelyn, M., Settle, C. D., McLain-Smith, S., & Marcella, S. W. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx174 · Cited by 78
Biosurfactants Change the Thinning of Contaminated Bubbles at Bacteria-Laden Water Interfaces
Poulain, S., & Bourouiba, L. (2018) · Physical Review Letters · doi:10.1103/physrevlett.121.204502 · Cited by 79
Real-Time Electronic Tracking of Diarrheal Episodes and Laxative Therapy Enables Verification of Clostridium difficile Clinical Testing Criteria and Reduction of Clostridium difficile Infection Rates
Truong, C., Gombar, S., Wilson, R., Sundararajan, G., Tekic, N., Holubar, M. K., Shepard, J. W., Madison, A. S., Tompkins, L. S., Shah, N., et al. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.02319-16 · Cited by 77
The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection
Seekatz, A. M., Safdar, N., & Khanna, S. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221134396 · Cited by 84
Cyclic diguanylate signaling in Gram-positive bacteria
Purcell, E. B., & Tamayo, R. (2016) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuw013 · Cited by 78
Silk Fibroin Microneedles for Transdermal Vaccine Delivery
Stinson, J. A., Raja, W. K., Lee, S., Kim, H. B., Diwan, I. M., Tutunjian, S., Panilaitis, B., Omenetto, F. G., Tzipori, S. R., & Kaplan, D. L. (2016) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6b00515 · Cited by 77
Antibiotic prescribing by general dentists in the United States, 2013
Roberts, R. M., Bartoces, M. G., Thompson, S. E., & Hicks, L. A. (2017) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2016.11.020 · Cited by 77
Laboratory Testing of Donors and Stool Samples for Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection
Woodworth, M. H., Neish, E., Miller, N. S., Dhere, T., Burd, E. M., Carpentieri, C., Sitchenko, K. L., & Kraft, C. S. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.02327-16 · Cited by 77
IL-17–producing γδ T cells protect against Clostridium difficile infection
Chen, Y.-S., Chen, I.-B. D., Pham, G. H., Shao, T., Bangar, H., Way, S. S., & Haslam, D. B. (2020) · Journal of Clinical Investigation · doi:10.1172/jci127242 · Cited by 73
Metagenome Data on Intestinal Phage-Bacteria Associations Aids the Development of Phage Therapy against Pathobionts
Fujimoto, K., Kimura, Y., Shimohigoshi, M., Satoh, T., Sato, S., Tremmel, G., Uematsu, M., Kawaguchi, Y., Usui, Y., Nakano, Y., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.005 · Cited by 79
The Sporobiota of the Human Gut
Egan, M., Dempsey, E. M., Ryan, C. A., Ross, R. P., & Stanton, C. (2021) · Gut Microbes · doi:10.1080/19490976.2020.1863134 · Cited by 79
Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection
Ross, C. L., Spinler, J. K., & Savidge, T. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.05.006 · Cited by 75
Complications, effectiveness, and long term follow‐up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection
van Beurden, Y. H., de Groot, P. F., van Nood, E., Nieuwdorp, M., Keller, J. J., & Goorhuis, A. (2016) · United European Gastroenterology Journal · doi:10.1177/2050640616678099 · Cited by 78
Trends in outpatient antibiotic use and prescribing practice among US older adults, 2011-15: observational study
Olesen, S. W., Barnett, M. L., MacFadden, D. R., Lipsitch, M., & Grad, Y. H. (2018) · BMJ · doi:10.1136/bmj.k3155 · Cited by 80
The role of gut microbiota in Clostridium difficile infection
Samarkos, M., Mastrogianni, E., & Kampouropoulou, O. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.02.006 · Cited by 75
Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial
Daley, P., Louie, T., Lutz, J. E., Khanna, S., Stoutenburgh, U., Jin, M., Adedoyin, A. B., Chesnel, L., Guris, D., Larson, K. B., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx299 · Cited by 75
TFPI is a colonic crypt receptor for TcdB from hypervirulent clade 2 C. difficile
Luo, J., Yang, Q., Zhang, X., Zhang, Y., Wan, L., Zhan, X., Zhou, Y., He, L., Li, D., Jin, D., et al. (2022) · Cell · doi:10.1016/j.cell.2022.02.010 · Cited by 75
Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection
Dubberke, E. R., Mullane, K. M., Gerding, D. N., Lee, C., Louie, T., Guthertz, H., & Jones, C. R. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw133 · Cited by 76
Self-citation
Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies
Hudson, L. E., Anderson, S. E., Corbett, A. H., & Lamb, T. J. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00049-16 · Cited by 76
Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection
Boix, V., Fedorak, R. N., Mullane, K. M., Pesant, Y., Stoutenburgh, U., Jin, M., Adedoyin, A. B., Chesnel, L., Güriş, D., Larson, K. B., et al. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw275 · Cited by 76
Clostridioides difficile infection in the Asia-Pacific region
Collins, D. A., Sohn, K. M., Wu, Y., Ouchi, K., Ishii, Y., Elliott, B., Riley, T. V., Tateda, K., & for the Clostridioides difficile Asia-Pacific Study Group (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1702480 · Cited by 74
Evaluating the Clinical Burden and Mortality Attributable to Antibiotic Resistance: The Disparity of Empirical Data and Simple Model Estimations
Abat, C., Rolain, J., Dubourg, G., Fournier, P., Chaudet, H., & Raoult, D. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix346 · Cited by 73
A Xylose-Inducible Expression System and a CRISPR Interference Plasmid for Targeted Knockdown of Gene Expression in Clostridioides difficile
Müh, U., Pannullo, A. G., Weiss, D. S., & Ellermeier, C. D. (2019) · Journal of Bacteriology · doi:10.1128/jb.00711-18 · Cited by 73
Microbiota-mediated protection against antibiotic-resistant pathogens
Panwar, R., Sequeira, R. P., & Clarke, T. B. (2021) · Genes and Immunity · doi:10.1038/s41435-021-00129-5 · Cited by 74
Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials
Lee, C., Louie, T., Bancke, L. L., Guthmueller, B., Harvey, A., Feuerstadt, P., Khanna, S., Orenstein, R., & Dubberke, E. R. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231174277 · Cited by 78
Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia
Chalmers, J. D., Akram, A. R., Singanayagam, A., Wilcox, M. H., & Hill, A. T. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.04.008 · Cited by 73
Management of inflammatory bowel disease withClostridium difficileinfection
D’Aoust, J., Battat, R. J., & Bessissow, T. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i27.4986 · Cited by 74
Vital Signs: Preventing Antibiotic-Resistant Infections in Hospitals — United States, 2014
Weiner, L. M., Fridkin, S. K., Torres, Z. A., Avery, L., Coffin, N., Dudeck, M. A., Edwards, J. R., Jernigan, J. A., Konnor, R. Y., Soe, M. M., et al. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6509e1 · Cited by 72
Self-citation
Fecal microbiota transplantation as a new therapy: from Clostridioides difficile infection to inflammatory bowel disease, irritable bowel syndrome, and colon cancer
Borody, T. J., Eslick, G. D., & Clancy, R. L. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.04.017 · Cited by 64
Gut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface
Sehgal, K., & Khanna, S. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284821994736 · Cited by 74
Insights into the Evolving Epidemiology of Clostridioides difficile Infection and Treatment: A Global Perspective
Liu, C. S., Monaghan, T. M., Yadegar, A., Louie, T., & Kao, D. H. (2023) · Antibiotics · doi:10.3390/antibiotics12071141 · Cited by 73
Clostridioides difficile Infection in Children: Recent Updates on Epidemiology, Diagnosis, Therapy
Shirley, D.-A. T., Tornel, W., Warren, C. A., & Moonah, S. N. (2023) · PEDIATRICS · doi:10.1542/peds.2023-062307 · Cited by 78
Antimicrobial Use, Human Gut Microbiota and Clostridium difficile Colonization and Infection
Vincent, C., & Manges, A. R. (2015) · Antibiotics · doi:10.3390/antibiotics4030230 · Cited by 76
Clostridium difficile Toxins TcdA and TcdB Cause Colonic Tissue Damage by Distinct Mechanisms
Chumbler, N. M., Farrow, M. A., Lapierre, L. A., Franklin, J. L., & Lacy, D. B. (2016) · Infection and Immunity · doi:10.1128/iai.00583-16 · Cited by 72
AAE Position Statement
(2017) · Journal of Endodontics · doi:10.1016/j.joen.2017.08.015 · Cited by 72
A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults
Sheldon, E. A., Kitchin, N. R. E., Peng, Y., Eiden, J., Gruber, W. C., Johnson, E. W., Jansen, K. U., Pride, M. W., & Pedneault, L. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.03.010 · Cited by 69
Metabolic Reprogramming of Clostridioides difficile During the Stationary Phase With the Induction of Toxin Production
Hofmann, J. D., Otto, A., Berges, M., Biedendieck, R., Michel, A., Becher, D., Jahn, D., & Neumann‐Schaal, M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01970 · Cited by 70
Clostridium difficile Infection and Fecal Microbiota Transplant
Liubakka, A. M., & Vaughn, B. P. (2016) · AACN Advanced Critical Care · doi:10.4037/aacnacc2016703 · Cited by 73
The incidence and drug resistance of Clostridium difficile infection in Mainland China: a systematic review and meta-analysis
Tang, C., Cui, L., Xu, Y., Xie, L., Sun, P., Liu, C., Xia, W., & Liu, G. (2016) · Scientific Reports · doi:10.1038/srep37865 · Cited by 71
The Effect of a Piperacillin/Tazobactam Shortage on Antimicrobial Prescribing and Clostridium difficile Risk in 88 US Medical Centers
Gross, A. E., Johannes, R. S., Gupta, V., Tabak, Y. P., Srinivasan, A., & Bleasdale, S. C. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix379 · Cited by 71
Fecal microbiota transplantation for the treatment of Clostridium difficile infection
Rao, K. K., & Safdar, N. (2015) · Journal of Hospital Medicine · doi:10.1002/jhm.2449 · Cited by 69
Facilely accessible quinoline derivatives as potent antibacterial agents
Teng, P., Li, C., Peng, Z., Marie, V. A., Nimmagadda, A., Su, M., Li, Y., Sun, X., & Cai, J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.05.031 · Cited by 70
U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin
Snydman, D. R., McDermott, L. A., Jacobus, N. V., Thorpe, C. M., Stone, S., Jenkins, S. G., Goldstein, E. J. C., Patel, R., Forbes, B. A., Mirrett, S., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00845-15 · Cited by 70
Self-citation

Authors: Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., Wilson, L. E., Winston, L. G., Cohen, J. A., Limbago, B. M., Fridkin, S. K., Gerding, D. N., & McDonald, L. C.
Affiliations: National Center for Emerging and Zoonotic Infectious Diseases (US)
Colorado Department of Public Health and Environment (US)
Oregon Health Authority (US)
University of Rochester Medicine (US)
Tennessee Department of Health (US)
Emory University (US)
Office of Readiness and Response (US)
Yale University (US)
University of New Mexico (US)
Maryland Department of Health (US)
University of California, San Francisco (US)
Loyola University Chicago (US)
ORCID: Lessa, Fernanda C.
Mu, Yi
Bamberg, Wendy M.
Dumyati, Ghinwa K.
Dunn, John R.
Farley, Monica M.
Holzbauer, Stacy M.
Meek, James I.
Phipps, Erin C.
Wilson, Lucy E.
Fridkin, Scott K.
Gerding, Dale N.
McDonald, L. Clifford
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-02-26
Volume: 372
Issue: 9
Pages: 825-834
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1408913
PMC: PMC10966662
OpenAlex: W2071054182
Cited by: 2,641
References: 44
Citations by year: 2026: 94 · 2025: 111 · 2024: 120 · 2023: 150 · 2022: 176 · 2021: 225 · 2020: 328 · 2019: 382 · 2018: 356 · 2017: 323 · 2016: 262 · 2015: 108
FWCI: 270.42
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: other-oa
Locations: New England Journal of Medicine (publishedVersion, other-oa)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Maryland Shared Open Access Repository (USMAI Consortium) (submittedVersion, public-domain)
eScholarship (California Digital Library) (submittedVersion)
Digital Repository at the University of Maryland (University of Maryland College Park) (public-domain)
Funders: National Institutes of Health (CC999999)
Centers for Disease Control and Prevention
Topics: Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
Keywords: Clostridium difficile infection, incidence, nosocomial infections, community-associated infections, recurrence, mortality, NAP1 strain, molecular typing, pulsed-field gel electrophoresis
MeSH terms: Adolescent, Adult, Aged, Child, Child, Preschool, Clostridium Infections, Cross Infection, Female, Humans, Infant, Male, Middle Aged, Population Surveillance, Recurrence, United States, Bacterial Typing Techniques, Incidence, Clostridioides difficile, Electrophoresis, Gel, Pulsed-Field, Age Distribution, Sex Distribution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Burden of Clostridium difficile Infection in the United States

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks